About Azanta
Azanta is a company based in Copenhagen (Denmark) founded in 1994 by Claus Juan Moller San Pedro was acquired by Norgine in March 2020.. Azanta has raised $15.82 million across 2 funding rounds from investors including Norgine, European Equity Partners and Norgine Ventures. The company has 3 employees as of December 31, 2018. Azanta operates in a competitive market with competitors including TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Candel Therapeutics, among others.
- Headquarter Copenhagen, Denmark
- Employees 3 as on 31 Dec, 2018
- Founders Claus Juan Moller San Pedro
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Azanta A/S
-
Annual Revenue
$6.92 K (USD)27as on Dec 31, 2018
-
Net Profit
$882.79 K (USD)0as on Dec 31, 2017
-
EBITDA
-
Total Equity Funding
$15.82 M (USD)
in 2 rounds
-
Latest Funding Round
$6.98 M (USD), Series B
Oct 01, 2015
-
Investors
Norgine
& 2 more
-
Employee Count
3
as on Dec 31, 2018
-
Acquired by
Norgine
(Mar 24, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Azanta
Azanta has successfully raised a total of $15.82M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $6.98 million completed in October 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $7.0M
-
First Round
First Round
(13 Oct 2014)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2015 | Amount | Series B - Azanta | Valuation | European Equity Partners |
|
| Oct, 2014 | Amount | Series B - Azanta | Valuation | Norgine Ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Azanta
Azanta has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Norgine, European Equity Partners and Norgine Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in life sciences companies is facilitated by EEP.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Proprietary therapeutic products for gastrointestinal diseases are developed and marketed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Azanta
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Azanta
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Azanta Comparisons
Competitors of Azanta
Azanta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Candel Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Antibody drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| domain | founded_year | HQ Location |
Viral immunotherapies are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
An immunotherapy platform for oncology and other diseases is developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Azanta
When was Azanta founded?
Azanta was founded in 1994 and raised its 1st funding round 20 years after it was founded.
Where is Azanta located?
Azanta is headquartered in Copenhagen, Denmark.
Who is the current CEO of Azanta?
Claus Juan Moller San Pedro is the current CEO of Azanta. They have also founded this company.
Is Azanta a funded company?
Azanta is a funded company, having raised a total of $15.82M across 2 funding rounds to date. The company's 1st funding round was a Series B of $8.84M, raised on Oct 13, 2014.
How many employees does Azanta have?
As of Dec 31, 2018, the latest employee count at Azanta is 3.
What is the annual revenue of Azanta?
Annual revenue of Azanta is $6.92K as on Dec 31, 2018.
What does Azanta do?
Azanta was founded in 1994 in Copenhagen, Denmark, focusing on the pharmaceutical and medical device sectors. Treatments for orphan oncology indications are developed, alongside devices for womens health monitoring. Lead candidates include Nimoral and Angusta. A range of specialty pharmaceutical products is marketed and distributed via third-party agreements. Operations center on intrauterine devices for contraception, such as the CE-approved Silverline Cu 380 and Flexi-T.
Who are the top competitors of Azanta?
Azanta's top competitors include Hummingbird Bioscience, Lyell Immunopharma and GigaGen.
Who are Azanta's investors?
Azanta has 3 investors. Key investors include Norgine, European Equity Partners, and Norgine Ventures.